Crispr Therapeutics AG (CRSP) Insider Trading
- $79,647,674.22
- $320,445,691.85
- March 23, 2026
- Samarth Kulkarni
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| May 14, 2018 | Director | 650,000 | $54.39 | Sell | $35,353,500.00 | |
| May 11, 2018 | Director | 250,000 | $52.84 | Sell | $13,210,000.00 | |
| May 8, 2018 | Director | 128,950 | $50.39 | Sell | $6,497,790.50 | |
| April 30, 2018 | Director | 30,566 | $50.29 | Sell | $1,537,164.14 | |
| April 27, 2018 | Director | 222,258 | $50.11 | Sell | $11,137,348.38 | |
| April 24, 2018 | Major Shareholder | 22,841 | $50.99 | Sell | $1,164,662.59 | |
| April 23, 2018 | Director | 101,994 | $50.68 | Sell | $5,169,055.92 | |
| Jan. 16, 2018 | Insider | 66,000 | $28.03 | Sell | $1,849,980.00 | |
| Jan. 5, 2018 | Director | 92,337 | $26.96 | Sell | $2,489,405.52 | |
| Jan. 5, 2018 | Major Shareholder | 527,472 | $22.75 | Buy | $11,999,988.00 | |
| Jan. 2, 2018 | Insider | 38,000 | $21.64 | Sell | $822,320.00 | |
| Jan. 2, 2018 | Director | 37,754 | $26.76 | Sell | $1,010,297.04 | |
| Dec. 29, 2017 | Insider | 31,000 | $22.72 | Sell | $704,320.00 | |
| Dec. 28, 2017 | Insider | 700 | $21.75 | Sell | $15,225.00 | |
| Dec. 22, 2017 | Director | 3,059 | $20.29 | Sell | $62,067.11 | |
| Dec. 22, 2017 | Insider | 15,000 | $20.55 | Sell | $308,250.00 | |
| Dec. 15, 2017 | Insider | 15,000 | $18.90 | Sell | $283,500.00 | |
| Dec. 4, 2017 | Major Shareholder | 1,112,446 | $18.98 | Sell | $21,114,225.08 | |
| Dec. 1, 2017 | Major Shareholder | 87,991 | $19.10 | Sell | $1,680,628.10 | |
| Nov. 29, 2017 | Major Shareholder | 4,263 | $19.25 | Sell | $82,062.75 | |
| Nov. 27, 2017 | Major Shareholder | 27,990 | $19.75 | Sell | $552,802.50 | |
| Nov. 27, 2017 | Director | 200 | $20.24 | Sell | $4,048.00 | |
| Nov. 24, 2017 | Major Shareholder | 26,010 | $20.00 | Sell | $520,200.00 | |
| Nov. 24, 2017 | Director | 1,700 | $20.21 | Sell | $34,357.00 | |
| Nov. 22, 2017 | Major Shareholder | 256,000 | $19.76 | Sell | $5,058,560.00 | |
| Nov. 20, 2017 | Major Shareholder | 158,718 | $19.02 | Sell | $3,018,816.36 | |
| Nov. 17, 2017 | Major Shareholder | 51,282 | $18.44 | Sell | $945,640.08 | |
| Nov. 15, 2017 | Major Shareholder | 15,000 | $17.67 | Sell | $265,050.00 | |
| Nov. 13, 2017 | Major Shareholder | 65,093 | $17.76 | Sell | $1,156,051.68 | |
| Nov. 10, 2017 | Major Shareholder | 10,000 | $17.28 | Sell | $172,800.00 | |
| Nov. 8, 2017 | Major Shareholder | 16,875 | $18.06 | Sell | $304,762.50 | |
| Nov. 6, 2017 | Major Shareholder | 79,327 | $18.89 | Sell | $1,498,487.03 | |
| Nov. 3, 2017 | Major Shareholder | 22,759 | $19.10 | Sell | $434,696.90 | |
| Sept. 5, 2017 | CEO | 18,470 | $20.76 | Sell | $383,437.20 | |
| Aug. 30, 2017 | CEO | 75,795 | $20.25 | Sell | $1,534,848.75 | |
| Aug. 30, 2017 | Insider | 27,154 | $20.08 | Sell | $545,252.32 | |
| Aug. 28, 2017 | Director | 88,011 | $19.79 | Sell | $1,741,737.69 | |
| Aug. 25, 2017 | Director | 22,781 | $19.42 | Sell | $442,407.02 | |
| Aug. 23, 2017 | Director | 17,989 | $18.53 | Sell | $333,336.17 | |
| Aug. 21, 2017 | Director | 3,150 | $18.52 | Sell | $58,338.00 | |
| Aug. 17, 2017 | Director | 34,141 | $19.06 | Sell | $650,727.46 | |
| Aug. 15, 2017 | Director | 55,569 | $19.59 | Sell | $1,088,596.71 | |
| Aug. 8, 2017 | Director | 35,473 | $18.63 | Sell | $660,861.99 | |
| Aug. 8, 2017 | Insider | 15,000 | $18.57 | Sell | $278,550.00 | |
| Aug. 4, 2017 | Director | 50,477 | $17.81 | Sell | $898,995.37 | |
| Aug. 1, 2017 | Director | 5,512 | $17.51 | Sell | $96,515.12 | |
| July 28, 2017 | Director | 41,312 | $17.63 | Sell | $728,330.56 | |
| July 26, 2017 | Director | 32,930 | $17.60 | Sell | $579,568.00 | |
| July 14, 2017 | Director | 69,859 | $16.84 | Sell | $1,176,425.56 | |
| July 12, 2017 | Director | 31,992 | $16.56 | Sell | $529,787.52 |
Insiders are both buying and selling Crispr Therapeutics AG stock.
The insider traders at Crispr Therapeutics AG are: Samarth Kulkarni, Rodger Novak, Kurt Von Emster, Bradley J Phd Bolzon, Corp /De/ Celgene, Tyler Dylan-Hyde, James R Kasinger, Pablo J Cagnoni, Thomas Woiwode, Lawrence Otto Klein, Vertex Pharmaceuticals (Europe, Naimish Patel, Julianne Bruno, Michael John Tomsicek, Simeon George, Aktiengesellschaft Bayer, Bradley J. Phd Bolzon, John Greene, Tony W Ho, Tony W. Ho, James R. Kasinger, Versant Venture Capital V, L.P, and Raju Prasad
The most active insider trader at Crispr Therapeutics AG is Samarth Kulkarni with 40 trades.
Kurt Von Emster has sold the most Crispr Therapeutics AG stock with a total value of $68,130,025.01.
Simeon George has bought the most Crispr Therapeutics AG stock with a total value of $103,930,836.72.
The most recent insider trade for Crispr Therapeutics AG was on March 23, 2026.
The single biggest insider buy for Crispr Therapeutics AG was from Simeon George with a total value of $51,499,918.36 on July 16, 2025.
The single biggest insider sell for Crispr Therapeutics AG was from Kurt Von Emster with a total value of $35,353,500.00 on May 14, 2018.
